Cagrilintide vs CagriSema
A side-by-side research comparison of Cagrilintide and CagriSema across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Cagrilintide | CagriSema |
|---|---|---|
| Full name | Cagrilintide (AM833) | CagriSema (Cagrilintide + Semaglutide) |
| Category | Weight Management | Weight Management |
| Status | Investigational (Phase III) | Phase 3 Clinical Trial |
| Mechanism | Acts as a dual amylin and calcitonin receptor agonist. It engages satiety centers in the area postrema and hindbrain, reducing food intake and slowing gastric emptying through a pathway distinct from GLP-1. | Dual-pathway activation: cagrilintide mimics amylin to activate area postrema satiety centers, while semaglutide activates GLP-1 receptors for complementary appetite suppression. |
| Molecular weight | ~3963 Da | Combination product |
| Half-life | ~7-8 days | 7 days (both components) |
| Bioavailability | High via subcutaneous injection | High (SubQ) |
| Typical dose | 0.3-2.4 mg (titrated) | Cagrilintide 2.4mg + Semaglutide 2.4mg |
| Frequency | Once weekly | Once weekly |
| Route | Subcutaneous injection | Subcutaneous |
Cagrilintide reported benefits
- Appetite suppression and increased satiety
- Meaningful weight loss
- Complements GLP-1 agonists (additive effect)
- Slows gastric emptying
CagriSema reported benefits
- Enhanced weight loss vs monotherapy
- Dual appetite suppression
- Convenient single injection
- Improved metabolic parameters
- Potential 20-25% weight loss
Related comparisons
Research and educational reference only. Not medical advice.